nirogacestat,lenalidomide,teclistamab,daratumumab,pomalidomide,bortezomib
takeda,springworks therapeutics,janssen,genmab,bms
['#160', 'teclistamab']
myeloma oral abstracts:
- teclistamab +dara sc (#160) bite (bcma-cd3)
- for r/r mm (prior lines 1-3) n=32
- low rates of crs, no icans
- higher rates of neutropenia (75%) sepsis (75%, g3/4 28%)
- orr 13/13 (100%) in evaluable pts effective, but very high % of sepsis ** #ash22
Guidelines, updates, Questions, Meetings in Hematology.